Newsroom

July 2020

• Featured News Jul 29, 2020

  Choice with Responsibility: Reimagining how we work

• Press release Jul 27, 2020

  Sandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in Europe

  Sandoz and Austrian government announce joint plans to drive long-term competitiveness of European production for key antibiotics in Europe Planned combined investment of more than EUR 150…
• Press release Jul 27, 2020

  New Novartis analysis shows wet AMD patients achieved sustained fluid control faster with Beovu® versus aflibercept

  A post-hoc analysis of the HAWK and HARRIER trials presented at ASRS showed >=50% of patients achieved sustained retinal dryness by weeks 8 and 4 with Beovu and by weeks 12 and 8 with aflibercept…
• 
  Story Jul 24, 2020 Discovery

  Breaking a vicious cycle of inflammation

  Novartis researchers aim to quash inflammation to treat chronic disease.

• Press release Jul 24, 2020

  Novartis Adakveo® receives positive CHMP opinion for the prevention of recurrent vaso-occlusive crises in patients with sickle cell disease

  If approved, Adakveo would be the first targeted sickle cell disease therapy available for use in Europe CHMP opinion supported by data showing Adakveo significantly reduced the rate of vaso-…
• Featured News Jul 24, 2020

  Expanding CAR-T manufacturing in Europe to serve more patients

  European Medicines Agency (EMA) recently approved two European Novartis sites for commercial CAR-T manufacturing.
• 
  Story Jul 23, 2020 Discovery

  Helping clinical trial patients during a lockdown

  Yan Zhao talks about how her team in China responded to an emerging public health crisis.

• Press release Jul 23, 2020

  Novartis announces Phase III study of Jakavi® in chronic graft-versus-host disease met primary and key secondary endpoints

  Jakavi® demonstrated superior overall response rate in patients with chronic graft-versus-host disease (GvHD) compared to best available therapy, building on previous positive findings in acute GvHD1…
• Ad hoc release Jul 21, 2020

  Novartis réalise une excellente performance au S1. Prévisions pour 2020 confirmées dans le haut de la fourchette pour le résultat opérationnel core et dans le bas pour le chiffre d’affaires.

  En raison du Covid-19 les résultats du S1 sont plus représentatifs de la performance sous-jacente que ceux du T2, croissance de 6% (tcc1, +3% USD) du chiffre d’affaires et de 19% (tcc, +14% USD) du…
• Ad hoc release Jul 21, 2020

  Novartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales.

  Due to COVID-19 first half results are more representative of underlying performance than Q2, sales growth of 6%  (cc1, +3% USD) and core¹ operating income growth of 19% (cc, +14% USD):…
• Ad hoc release Jul 21, 2020

  Novartis erzielte im ersten Halbjahr eine starke Performance. Die Jahresprognose 2020 für das operative Kernergebnis bzw. den Umsatz wurde am oberen bzw. unteren Ende früherer Voraussagen bestätigt.

  Aufgrund von COVID-19 sind die Ergebnisse des ersten Halbjahres repräsentativer für die zugrundeliegende Performance als die Ergebnisse des zweiten Quartals; Umsatzwachstum von 6% (kWk1, +3% USD…
• Press release Jul 16, 2020

  Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19

  Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division addresses urgent unmet needs of low- and lower-middle-income countries to treat patients with COVID-19…